NNNN Fundamental Analysis - ANBIO BIOTECHNOLOGY LTD

Fundamental Rating

Taking everything into account, NNNN scores 6 out of 10 in our fundamental rating. NNNN was compared to 536 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making NNNN a very profitable company, without any liquidiy or solvency issues. While showing a medium growth rate, NNNN is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year NNNN was profitable.

In the past year NNNN has reported a negative cash flow from operations.

1.2 Ratios

Looking at the Return On Assets, with a value of 30.88%, NNNN belongs to the top of the industry, outperforming 98.32% of the companies in the same industry.

Looking at the Return On Equity, with a value of 31.77%, NNNN belongs to the top of the industry, outperforming 97.39% of the companies in the same industry.

NNNN's Return On Invested Capital of 23.85% is amongst the best of the industry. NNNN outperforms 97.95% of its industry peers.

The Average Return On Invested Capital over the past 3 years for NNNN is significantly above the industry average of 15.47%.

The last Return On Invested Capital (23.85%) for NNNN is well below the 3 year average (27.94%), which needs to be investigated, but indicates that NNNN had better years and this may not be a problem.

		Industry Rank	Sector Rank
ROA	30.88%
ROE	31.77%
ROIC	23.85%

ROA(3y)32.84%

ROA(5y)N/A

ROE(3y)36.27%

ROE(5y)N/A

ROIC(3y)27.94%

ROIC(5y)N/A

1.3 Margins

Looking at the Profit Margin, with a value of 46.57%, NNNN belongs to the top of the industry, outperforming 98.69% of the companies in the same industry.

NNNN's Profit Margin has declined in the last couple of years.

With an excellent Operating Margin value of 44.26%, NNNN belongs to the best of the industry, outperforming 99.25% of the companies in the same industry.

In the last couple of years the Operating Margin of NNNN has declined.

NNNN's Gross Margin of 57.89% is fine compared to the rest of the industry. NNNN outperforms 77.99% of its industry peers.

NNNN's Gross Margin has improved in the last couple of years.

		Industry Rank	Sector Rank
OM	44.26%
PM (TTM)	46.57%
GM	57.89%

OM growth 3Y-23.96%

OM growth 5YN/A

PM growth 3Y-20.3%

PM growth 5YN/A

GM growth 3Y7.8%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), NNNN is creating value.

NNNN has about the same amout of shares outstanding than it did 1 year ago.

NNNN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 1480.51 indicates that NNNN is not in any danger for bankruptcy at the moment.

Looking at the Altman-Z score, with a value of 1480.51, NNNN belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.

There is no outstanding debt for NNNN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	1480.51

ROIC/WACC3.26

WACC7.31%

2.3 Liquidity

A Current Ratio of 35.56 indicates that NNNN has no problem at all paying its short term obligations.

NNNN has a Current ratio of 35.56. This is amongst the best in the industry. NNNN outperforms 98.32% of its industry peers.

A Quick Ratio of 35.56 indicates that NNNN has no problem at all paying its short term obligations.

NNNN has a better Quick ratio (35.56) than 98.32% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	35.56
Quick Ratio	35.56

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

NNNN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.95%, which is quite impressive.

The Earnings Per Share has been decreasing by -2.10% on average over the past years.

The Revenue has grown by 43.63% in the past year. This is a very strong growth!

Measured over the past years, NNNN shows a very strong growth in Revenue. The Revenue has been growing by 22.72% on average per year.

EPS 1Y (TTM)57.95%

EPS 3Y-2.1%

EPS 5YN/A

EPS Q2Q%6.37%

Revenue 1Y (TTM)43.63%

Revenue growth 3Y22.72%

Revenue growth 5YN/A

Sales Q2Q%21.95%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

NNNN is valuated quite expensively with a Price/Earnings ratio of 739.75.

Based on the Price/Earnings ratio, NNNN is valued cheaper than 89.93% of the companies in the same industry.

NNNN is valuated expensively when we compare the Price/Earnings ratio to 27.70, which is the current average of the S&P500 Index.

		Industry Rank	Sector Rank
PE	739.75
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

NNNN has a very decent profitability rating, which may justify a higher PE ratio.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

NNNN does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ANBIO BIOTECHNOLOGY LTD

NASDAQ:NNNN (10/9/2025, 9:30:42 PM)

After market: 29.59 0 (0%)

29.59

-1.4 (-4.52%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)04-28 2025-04-28

Earnings (Next)N/A N/A

Inst Owners4.85%

Inst Owner ChangeN/A

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap1.30B

AnalystsN/A

Price TargetN/A

Short Float %0.39%

Short Ratio2.13

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	739.75
Fwd PE	N/A
P/S	103.39
P/FCF	N/A
P/OCF	N/A
P/B	70.52
P/tB	70.52
EV/EBITDA	N/A

EPS(TTM)0.04

EY0.14%

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-0.01

FCFYN/A

OCF(TTM)-0.01

OCFYN/A

SpS0.29

BVpS0.42

TBVpS0.42

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	30.88%
ROE	31.77%
ROCE	30.19%
ROIC	23.85%
ROICexc	54.19%
ROICexgc	54.19%
OM	44.26%
PM (TTM)	46.57%
GM	57.89%
FCFM	N/A

ROA(3y)32.84%

ROA(5y)N/A

ROE(3y)36.27%

ROE(5y)N/A

ROIC(3y)27.94%

ROIC(5y)N/A

ROICexc(3y)88.97%

ROICexc(5y)N/A

ROICexgc(3y)88.97%

ROICexgc(5y)N/A

ROCE(3y)35.37%

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3Y-23.96%

OM growth 5YN/A

PM growth 3Y-20.3%

PM growth 5YN/A

GM growth 3Y7.8%

GM growth 5YN/A

F-Score4

Asset Turnover0.66

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	35.56
Quick Ratio	35.56
Altman-Z	1480.51

F-Score4

WACC7.31%

ROIC/WACC3.26

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)57.33%

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)57.95%

EPS 3Y-2.1%

EPS 5YN/A

EPS Q2Q%6.37%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)43.63%

Revenue growth 3Y22.72%

Revenue growth 5YN/A

Sales Q2Q%21.95%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-52.14%

EBIT growth 3Y-6.69%

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y131.57%

FCF growth 3Y-20.76%

FCF growth 5YN/A

OCF growth 1Y131.57%

OCF growth 3Y-20.76%

OCF growth 5YN/A

ANBIO BIOTECHNOLOGY LTD (NNNN) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens